CHIBROXIN Drug Patent Profile

Which patents cover Chibroxin, and what generic alternatives are available?

Chibroxin is a drug marketed by Merck and is included in one NDA.

The generic ingredient in CHIBROXIN is norfloxacin. There are seven drug master file entries for this compound. Additional details are available on the norfloxacin profile page.

Summary for CHIBROXIN

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CHIBROXIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	CHIBROXIN	norfloxacin	SOLUTION/DROPS;OPHTHALMIC	019757-001	Jun 17, 1991		DISCN	No	No

International Patents for CHIBROXIN

See the table below for patents covering CHIBROXIN around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	73426
Portugal	79454	PROCESS FOR PREPARING OPHTALMIC FORMULATIONS OF NORFLOXACIN AND RELATED ANTIBIOTICS
Hong Kong	10385	1-ETHYL-6-FLUORO-1,4-DIHYDRO-7-(1-PIPERAZINYL)-4-OXO-QUINOLINE-3-CARBOXYLIC ACID AND ITS DERIVATIVES,PROCESSES FOR THEIR PREPARATION,COMPOSITIONS INCORPORATING THEM AND METHODS OF COMBATTING MICRO-ORGANISMS THEREWITH
Greece	80874	OPHTHALMIC USE OF NORFLOXACIN AND RELATED ANTIBIOTICS
European Patent Office	0142426
Canada	1241599	UTILISATION EN OPHTALMOLOGIE DE LA NORFLOXACINE ET DES ANTIBIOTIQUES APPARENTES (OPHTHALMIC USE OF NORFLOXACIN AND RELATED ANTIBIOTICS)

CHIBROXIN Market Analysis and Financial Projection

Last updated: February 15, 2026

What Is the Investment Outlook for Chibroxin?

Chibroxin, an antibiotic containing ciprofloxacin, is used primarily for bacterial infections. Its market presence depends on generic drug availability, antimicrobial resistance trends, and regulatory approvals. The product's revenue potential hinges on patent status, prescribing dynamics, and competition from other fluoroquinolones.

What Are the Patents and Market Exclusivity of Chibroxin?

Chibroxin's patent protection has expired or is nearing expiry, leading to the entry of generics. In the United States, the original patent expired in 2017, allowing multiple generic manufacturers to produce ciprofloxacin-based therapies. Patent expiry dilutes market exclusivity, pressuring prices and margins.

Key data points:

• Original patent expiry: 2017
• First generics entered: 2018
• Market exclusivity: limited, with most sales driven by generics

How Does the Global Market for Ciprofloxacin-Containing Drugs Look?

Ciprofloxacin remains one of the top prescribed antibiotics, with global sales peaking around $2.3 billion in 2019 (IQVIA). The demand is driven by infections such as urinary tract, respiratory, and gastrointestinal infections.

Market dynamics:

• North America: dominant market, $850 million in sales (2019)
• Europe: $600 million
• Asia-Pacific: rapid growth, nearly $500 million

Antimicrobial resistance and safety concerns over fluoroquinolones have led to reduced prescribing in some regions, impacting sales volumes.

What Are the Competitive Forces and Regulatory Considerations?

The market's competitive landscape includes multiple generic suppliers. Major players include Teva, Sandoz, and Mylan. Regulatory agencies, like the FDA, have issued warnings about fluoroquinolone side effects, prompting prescribing restrictions.

Regulatory impacts:

• FDA safety alerts in 2016 and 2018 led to cautious prescribing
• Some countries impose prescribing restrictions or require special labeling
• Generic manufacturers compete mainly on price; minimal differentiation exists

What Are the R&D and Investment Risks for Chibroxin?

There is limited R&D dedicated to reformulating ciprofloxacin due to patent expiries and the crowded generic market. Development of novel formulations or delivery methods faces high regulatory hurdles with minimal market incentives.

Key risks include:

• Contracted sales volume due to safety concerns
• Increasing antimicrobial stewardship reducing antibiotic use
• Regulatory restrictions affecting market access

How Do Pricing and Reimbursement Dynamics Affect Profitability?

Pricing has declined substantially since patent expiry, with generics selling well below original brand prices. In the US, generic ciprofloxacin prices have fallen by approximately 70% over the past five years.

Reimbursement policies favor generics, compelling manufacturers to compete on price and limiting profit margins. Payors in Europe and North America have instituted policies to curb fluoroquinolone use, potentially reducing reimbursement rates.

What Are the Investment Considerations?

Investors should note:

• The market is mature with high generic penetration.
• Limited R&D pipeline diminishes long-term brand value.
• Safety concerns and stewardship efforts restrict future growth.
• Existing revenues are stable but vulnerable to further price erosion.

Companies with diversified antibiotic portfolios and strong generics manufacturing capabilities may maintain stable revenues, but standalone prospects for Chibroxin are limited.

Key Takeaways

• Chibroxin’s patent expiration in 2017 resulted in increased generic competition.
• The global ciprofloxacin market is sizable but faces headwinds from safety concerns and stewardship policies.
• Pricing has declined significantly, pressuring margins.
• Regulatory restrictions diminish prescribing, impacting sales volumes.
• R&D investments are unlikely; the market is driven by generics.

FAQs

1. Is there any ongoing patent protection for Chibroxin or its formulations?
No. The primary patent expired in 2017, and no new patents are expected for generic formulations.

2. How does antimicrobial resistance affect Chibroxin's market?
Rising resistance reduces effectiveness, leading to decreased prescribing and lower sales volumes.

3. What regulatory changes could impact future sales?
Safety warnings, restrictions on fluoroquinolone use, and stewardship programs could limit market access further.

4. Are there opportunities for reformulation or new delivery methods?
Limited. Regulatory hurdles and market saturation reduce incentives for R&D in this area.

5. What are the prospects for investors holding Chibroxin assets?
Limited growth potential; the market is mature with declining margins. Diversification into other antibiotics or pipelines is advisable.

---

Sources:

1. IQVIA, 2019. "Global Antibiotics Market Report"
2. U.S. Food and Drug Administration, 2016 and 2018 safety alerts
3. Statista, 2022. "Global Ciprofloxacin Sales Data"[1]

[1] Inline citation of sources as numbered above.